Pulmonary coccidioidomycosis
ICD-10 B39.0 is a billable code used to indicate a diagnosis of pulmonary coccidioidomycosis.
Pulmonary coccidioidomycosis is a fungal infection caused by the inhalation of spores from the Coccidioides species, primarily C. immitis and C. posadasii. This condition is endemic to certain regions, particularly the southwestern United States, parts of Mexico, and Central and South America. The infection can range from asymptomatic to severe pulmonary disease, with symptoms including cough, fever, chest pain, and fatigue. In immunocompromised patients, such as those with HIV/AIDS, cancer, or those on immunosuppressive therapy, the risk of disseminated disease is significantly increased. Diagnosis is typically made through clinical evaluation, serological tests, and imaging studies such as chest X-rays or CT scans. Treatment often involves antifungal medications, with fluconazole and itraconazole being the most commonly prescribed. In severe cases, amphotericin B may be indicated. Early recognition and appropriate management are crucial to prevent complications, especially in vulnerable populations.
Detailed patient history, including travel history and immunocompromised status.
Patients presenting with respiratory symptoms and a history of exposure in endemic areas.
Consideration of co-infections and the need for comprehensive treatment plans.
Pulmonary function tests, imaging studies, and symptom assessment.
Patients with chronic cough and abnormal chest imaging.
Monitoring for potential complications such as lung abscesses or disseminated disease.
Used to confirm diagnosis in suspected cases.
Document the reason for testing and clinical findings.
Infectious disease specialists may order this test more frequently.
Common symptoms include cough, fever, chest pain, fatigue, and in severe cases, difficulty breathing. Some patients may be asymptomatic.
